{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T20:08:32Z","timestamp":1782763712856,"version":"3.54.5"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,3,17]],"date-time":"2016-03-17T00:00:00Z","timestamp":1458172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,3,17]],"date-time":"2016-03-17T00:00:00Z","timestamp":1458172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Sepsis is the principal cause of fatality in the intensive care units worldwide. It involves uncontrolled inflammatory response resulting in multi-organ failure and even death. Micheliolide (MCL), a sesquiterpene lactone, was reported to inhibit dextran sodium sulphate (DSS)-induced inflammatory intestinal disease, colitis-associated cancer and rheumatic arthritis. Nevertheless, the role of MCL in microbial infection and sepsis is unclear. We demonstrated that MCL decreased lipopolysaccharide (LPS, the main cell wall component of Gram-negative bacteria)-mediated production of cytokines (IL-6, TNF-\u03b1, MCP-1, etc) in Raw264.7 cells, primary macrophages, dendritic cells and human monocytes. MCL plays an anti-inflammatory role by inhibiting LPS-induced activation of NF-\u03baB and PI3K\/Akt\/p70S6K pathways. It has negligible impact on the activation of mitogen-activated protein kinase (MAPK) pathways. In the acute peritonitis mouse model, MCL reduced the secretion of IL-6, TNF-\u03b1, IL-1\u03b2, MCP-1, IFN-\u03b2 and IL-10 in sera and ameliorated lung and liver damage. MCL down-regulated the high mortality rate caused by lethal LPS challenge. Collectively, our data illustrated that MCL enabled maintenance of immune equilibrium may represent a potentially new anti-inflammatory and immunosuppressive drug candidate in the treatment of sepsis and septic shock.<\/jats:p>","DOI":"10.1038\/srep23240","type":"journal-article","created":{"date-parts":[[2016,3,17]],"date-time":"2016-03-17T10:02:02Z","timestamp":1458208922000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["Micheliolide inhibits LPS-induced inflammatory response and protects mice from LPS challenge"],"prefix":"10.1038","volume":"6","author":[{"given":"Xiangyang","family":"Qin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinru","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhulei","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weigang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guizhen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhui","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuejuan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,17]]},"reference":[{"key":"BFsrep23240_CR1","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1097\/CCM.0b013e31827c09f8","volume":"41","author":"DF Gaieski","year":"2013","unstructured":"Gaieski, D. F., Edwards, J. M., Kallan, M. J. & Carr, B. G. Benchmarking the incidence and mortality of severe sepsis in the United States. Crit. Care Med. 41, 1167\u20131174 (2013).","journal-title":"Crit. Care Med."},{"key":"BFsrep23240_CR2","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/S1473-3099(12)70136-6","volume":"12","author":"J Cohen","year":"2012","unstructured":"Cohen, J., Opal, S. & Calandra, T. Sepsis studies need new direction. Lancet Infect. Dis. 12, 503\u2013505 (2012).","journal-title":"Lancet Infect. Dis."},{"key":"BFsrep23240_CR3","unstructured":"Torio, C. A. & Andrews, R. A. in Agency for Healthcare Research and Quality (Rockville, MD, 2013)."},{"key":"BFsrep23240_CR4","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1001\/jama.2010.1553","volume":"304","author":"TJ Iwashyna","year":"2010","unstructured":"Iwashyna, T. J., Ely, E. W., Smith, D. M. & Langa, K. M. Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA 304, 1787\u20131794 (2010).","journal-title":"JAMA"},{"key":"BFsrep23240_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3389\/fimmu.2013.00387","volume":"4","author":"A Savva","year":"2013","unstructured":"Savva, A. & Roger, T. Targeting Toll-like receptors: Promising therapeutic strategies for the management of sepsis-associated pathology and infectious diseases. Front. Immunol. 4, 387 (2013).","journal-title":"Front. Immunol."},{"key":"BFsrep23240_CR6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S1473-3099(09)70066-0","volume":"9","author":"E Lappin","year":"2009","unstructured":"Lappin, E. & Ferguson, A. J. Gram-positive toxic shock syndromes. Lancet Infect. Dis. 9, 281\u2013290 (2009).","journal-title":"Lancet Infect. Dis."},{"key":"BFsrep23240_CR7","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/nrd4368","volume":"13","author":"MP Fink","year":"2014","unstructured":"Fink, M. P. & Warren, H. S. Strategies to improve drug development for sepsis. Nat. Rev. Drug Discov. 13, 741\u2013758 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFsrep23240_CR8","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.1128\/AAC.00534-10","volume":"54","author":"T Gutsmann","year":"2010","unstructured":"Gutsmann, T. et al. New antiseptic peptides to protect against endotoxin-mediated shock. Antimicrob. Agents Chemother. 54, 3817\u20133824 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep23240_CR9","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1128\/AAC.02066-12","volume":"57","author":"L Heinbockel","year":"2013","unstructured":"Heinbockel, L. et al. Preclinical investigations reveal the broad-spectrum neutralizing activity of peptide Pep19-2.5 on bacterial pathogenicity factors. Antimicrob. Agents Chemother. 57, 1480\u20131487 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep23240_CR10","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2174\/1874091X01307010082","volume":"7","author":"D Sil","year":"2013","unstructured":"Sil, D. et al. Biophysical Mechanisms of the Neutralization of Endotoxins by Lipopolyamines. Open Biochem. J. 7, 82\u201393 (2013).","journal-title":"Open Biochem. J."},{"key":"BFsrep23240_CR11","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nri2079","volume":"7","author":"LA O\u2019Neill","year":"2007","unstructured":"O\u2019Neill, L. A. & Bowie, A. G. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat. Rev. Immunol. 7, 353\u2013364 (2007).","journal-title":"Nat. Rev. Immunol."},{"key":"BFsrep23240_CR12","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1126\/science.7878466","volume":"267","author":"K Brown","year":"1995","unstructured":"Brown, K., Gerstberger S., Carlson, L., Franzoso, G. & Siebenlist, U. Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation. Science 267, 1485\u20131488 (1995).","journal-title":"Science"},{"key":"BFsrep23240_CR13","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/nri2711","volume":"10","author":"M Saraiva","year":"2010","unstructured":"Saraiva, M. & O\u2019Garra, A. The regulation of IL-10 production by immune cells. Nat. Rev. Immunol. 10, 170\u2013181 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"BFsrep23240_CR14","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.drudis.2008.07.004","volume":"13","author":"AL Harvey","year":"2008","unstructured":"Harvey, A. L. Natural products in drug discovery. Drug Discov. Today 13, 894\u2013901 (2008).","journal-title":"Drug Discov. Today"},{"key":"BFsrep23240_CR15","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/anie.198500941","volume":"24","author":"HMR Hoffmann","year":"1985","unstructured":"Hoffmann, H. M. R. & Rabe, J. Synthesis and Biological Activity of \u03b1-Methylene-\u03b3-butyrolactones. Angew. Chem. Int. Ed. 24, 94\u2013110 (1985).","journal-title":"Angew. Chem. Int. Ed."},{"key":"BFsrep23240_CR16","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/0305-1978(86)90101-8","volume":"14","author":"AK Picman","year":"1986","unstructured":"Picman, A. K. Biological activities of sesquiterpene lactones, Biochem. Syst. Ecol. 14, 255\u2013281 (1986).","journal-title":"Biochem. Syst. Ecol."},{"key":"BFsrep23240_CR17","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.drudis.2010.06.002","volume":"15","author":"A Ghantous","year":"2010","unstructured":"Ghantous, A., Gali-Muhtasib, H., Vuorela, H., Saliba, N. A. & Darwiche, N. What made sesquiterpene lactones reach cancer clinical trials? Drug Discov. Today 15, 668\u2013678 (2010).","journal-title":"Drug Discov. Today"},{"key":"BFsrep23240_CR18","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0031-9422(00)88656-2","volume":"17","author":"M Ogura","year":"1978","unstructured":"Ogura, M., Cordell, G. A. & Farnsworth, N. R. Anticancer sesquiterpene lactones of Michelia compressa (Magnoliaceae). Phytochemistry 17, 957\u2013961 (1978).","journal-title":"Phytochemistry"},{"key":"BFsrep23240_CR19","doi-asserted-by":"publisher","first-page":"13061","DOI":"10.3390\/molecules181013061","volume":"18","author":"QQ Jia","year":"2013","unstructured":"Jia, Q. Q. et al. Sesquiterpene lactones and their derivatives inhibit high glucose-induced NF-\u03baB activation and MCP-1 and TGF-\u03b21 expression in rat mesangial cells. Molecules 18, 13061\u201313077 (2013).","journal-title":"Molecules"},{"key":"BFsrep23240_CR20","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.cell.2006.02.015","volume":"124","author":"S Akira","year":"2006","unstructured":"Akira, S., Uematsu, S. & Takeuchi, O. Pathogen recognition and innate immunity. Cell 124, 783\u2013801 (2006).","journal-title":"Cell"},{"key":"BFsrep23240_CR21","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S0014-5793(97)00323-2","volume":"410","author":"N Pullen","year":"1997","unstructured":"Pullen, N. & Thomas, G. The modular phosphorylation and activation of p70s6k. FEBS Lett. 410, 78\u201382 (1997).","journal-title":"FEBS Lett."},{"key":"BFsrep23240_CR22","doi-asserted-by":"publisher","first-page":"16621","DOI":"10.1074\/jbc.273.26.16621","volume":"273","author":"QP Weng","year":"1998","unstructured":"Weng, Q. P. et al. Regulation of the p70 S6 kinase by phosphorylation in vivo. Analysis using site-specific anti-phosphopeptide antibodies. J. Biol. Chem. 273, 16621\u201316629 (1998).","journal-title":"J. Biol. Chem."},{"key":"BFsrep23240_CR23","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.immuni.2006.10.014","volume":"25","author":"H An","year":"2006","unstructured":"An, H. et al. SHP-2 phosphatase negatively regulates the TRIF adaptor protein-dependent type I interferon and proinflammatory cytokine production. Immunity 25, 919\u2013928 (2006).","journal-title":"Immunity"},{"key":"BFsrep23240_CR24","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/S1471-4906(03)00079-6","volume":"24","author":"MG Netea","year":"2003","unstructured":"Netea, M. G., van der Meer, J. W., van Deuren, M. & Kullberg, B. J. Proinflammatory cytokines and sepsis syndrome: not enough, or too much of a good thing? Trends Immunol. 24, 254\u2013258 (2003).","journal-title":"Trends Immunol."},{"key":"BFsrep23240_CR25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.4161\/viru.25436","volume":"5","author":"WJ Wiersinga","year":"2014","unstructured":"Wiersinga, W. J., Leopold, S. J., Cranendonk, D. R. & van der Poll, T. Host innate immune responses to sepsis. Virulence 5, 36\u201344 (2014).","journal-title":"Virulence"},{"key":"BFsrep23240_CR26","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/CCM.0b013e3181b07b78","volume":"38","author":"M Tidswell","year":"2010","unstructured":"Tidswell, M. et al. Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis. Crit. Care Med. 38, 72\u201383 (2010).","journal-title":"Crit. Care Med."},{"key":"BFsrep23240_CR27","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/nrd4016","volume":"12","author":"MT Tse","year":"2013","unstructured":"Tse, M. T. Trial watch: Sepsis study failure highlights need for trial design rethink. Nat. Rev. Drug Discov. 12, 334 (2013).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFsrep23240_CR28","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.intimp.2012.03.005","volume":"13","author":"Y Zheng","year":"2012","unstructured":"Zheng, Y. et al. Ephedrine hydrochloride protects mice from LPS challenge by promoting IL-10 secretion and inhibiting proinflammatory cytokines. Int. Immunopharmacol. 13, 46\u201353 (2012).","journal-title":"Int. Immunopharmacol."},{"key":"BFsrep23240_CR29","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/cmi.2013.3","volume":"10","author":"Y Zheng","year":"2013","unstructured":"Zheng, Y. et al. Ephedrine hydrochloride inhibits PGN-induced inflammatory responses by promoting IL-10 production and decreasing proinflammatory cytokine secretion via the PI3K\/Akt\/GSK3\u03b2 pathway. Cell. Mol. Immunol. 10, 330\u2013337 (2013).","journal-title":"Cell. Mol. Immunol."},{"key":"BFsrep23240_CR30","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/labinvest.2014.89","volume":"94","author":"E Viennois","year":"2014","unstructured":"Viennois, E. et al. Micheliolide, a new sesquiterpene lactone that inhibits intestinal inflammation and colitis-associated cancer. Lab Invest 94, 950\u2013965 (2014).","journal-title":"Lab Invest"},{"key":"BFsrep23240_CR31","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3892\/mmr.2014.2767","volume":"11","author":"H Xu","year":"2015","unstructured":"Xu, H. et al. Therapeutic effects of micheliolide on a murine model of rheumatoid arthritis. Mol. Med. Rep. 11, 489\u2013493 (2015).","journal-title":"Mol. Med. Rep."},{"key":"BFsrep23240_CR32","doi-asserted-by":"publisher","first-page":"8757","DOI":"10.1021\/jm301064b","volume":"55","author":"Q Zhang","year":"2012","unstructured":"Zhang, Q. et al. Guaianolide sesquiterpene lactones, a source to discover agents that selectively inhibit acute myelogenous leukemia stem and progenitor cells. J. Med. Chem. 55, 8757\u20138769 (2012).","journal-title":"J. Med. Chem."},{"key":"BFsrep23240_CR33","first-page":"R269","volume":"275","author":"LR Leon","year":"1998","unstructured":"Leon, L. R., White, A. A. & Kluger, M. J. Role of IL-6 and TNF in thermoregulation and survival during sepsis in mice. Am. J. Physiol. 275, R269\u2013277 (1998).","journal-title":"Am. J. Physiol."},{"key":"BFsrep23240_CR34","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1097\/00003246-200209000-00007","volume":"30","author":"A Geppert","year":"2002","unstructured":"Geppert, A. et al. Multiple organ failure in patients with cardiogenic shock is associated with high plasma levels of interleukin-6. Crit. Care Med. 30, 1987\u20131994 (2002).","journal-title":"Crit. Care Med."},{"key":"BFsrep23240_CR35","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1471-2334-5-51","volume":"5","author":"EJ Giamarellos-Bourboulis","year":"2005","unstructured":"Giamarellos-Bourboulis, E. J. et al. Immunomodulatory intervention in sepsis by multidrug-resistant Pseudomonas aeruginosa with thalidomide: an experimental study. BMC Infect. Dis. 5, 51 (2005).","journal-title":"BMC Infect. Dis."},{"key":"BFsrep23240_CR36","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S1473-3099(07)70265-7","volume":"8","author":"T van der Poll","year":"2008","unstructured":"van der Poll, T. & Opal, S. M. Host-pathogen interactions in sepsis. Lancet Infect. Dis. 8, 32\u201343 (2008).","journal-title":"Lancet Infect. Dis."},{"key":"BFsrep23240_CR37","doi-asserted-by":"publisher","first-page":"11355","DOI":"10.1038\/srep11355","volume":"5","author":"M Surbatovic","year":"2015","unstructured":"Surbatovic, M. et al. Cytokine profile in severe Gram-positive and Gram-negative abdominal sepsis. Sci. Rep. 5, 11355 (2015).","journal-title":"Sci. Rep."},{"key":"BFsrep23240_CR38","doi-asserted-by":"publisher","first-page":"384","DOI":"10.4049\/jimmunol.169.1.384","volume":"169","author":"Y Kalechman","year":"2002","unstructured":"Kalechman, Y. et al. Anti-IL-10 therapeutic strategy using the immunomodulator AS101 in protecting mice from sepsis-induced death: dependence on timing of immunomodulating intervention. J. Immunol. 169, 384\u2013392 (2002).","journal-title":"J. Immunol."},{"key":"BFsrep23240_CR39","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1146\/annurev-immunol-032414-112240","volume":"33","author":"SW Brubaker","year":"2015","unstructured":"Brubaker, S. W., Bonham, K. S., Zanoni, I. & Kagan, J. C. Innate immune pattern recognition: a cell biological perspective. Annu. Rev. Immunol. 33, 257\u2013290 (2015).","journal-title":"Annu. Rev. Immunol."},{"key":"BFsrep23240_CR40","doi-asserted-by":"publisher","first-page":"6447","DOI":"10.4049\/jimmunol.0901750","volume":"184","author":"Y Zheng","year":"2010","unstructured":"Zheng, Y. et al. Scaffolding adaptor protein Gab1 is required for TLR3\/4- and RIG-I-mediated production of proinflammatory cytokines and type I IFN in macrophages. J. Immunol. 184, 6447\u20136456 (2010).","journal-title":"J. Immunol."},{"key":"BFsrep23240_CR41","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1182\/blood-2011-08-377242","volume":"120","author":"L Qian","year":"2012","unstructured":"Qian, L. et al. Regulatory dendritic cells program B cells to differentiate into CD19hiFc\u03b3IIbhi regulatory B cells through IFN-\u03b2 and CD40L. Blood 120, 581\u2013591 (2012).","journal-title":"Blood"},{"key":"BFsrep23240_CR42","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/ni.1908","volume":"11","author":"C Han","year":"2010","unstructured":"Han, C. et al. Integrin CD11b negatively regulates TLR-triggered inflammatory responses by activating Syk and promoting degradation of MyD88 and TRIF via Cbl-b. Nat. Immunol. 11, 734\u2013742 (2010).","journal-title":"Nat. Immunol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep23240","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep23240.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep23240.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T13:04:04Z","timestamp":1672837444000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep23240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,17]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,9,2]]}},"alternative-id":["BFsrep23240"],"URL":"https:\/\/doi.org\/10.1038\/srep23240","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,17]]},"assertion":[{"value":"12 October 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23240"}}